Search Results - "Petty, D R"

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas by Bain, G H, Collie-Duguid, E, Murray, G I, Gilbert, F J, Denison, A, Mckiddie, F, Ahearn, T, Fleming, I, Leeds, J, Phull, P, Park, K, Nanthakumaran, S, Grabsch, H I, Tan, P, Welch, A, Schweiger, L, Dahle-Smith, A, Urquhart, G, Finegan, M, Petty, R D

“…Background: Cytotoxic chemotherapy remains the main systemic therapy for gastro-oesophageal adenocarcinoma, but resistance to chemotherapy is common, resulting…”
Get full text

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report by Okines, A.F.C., Langley, R.E., Thompson, L.C., Stenning, S.P., Stevenson, L., Falk, S., Seymour, M., Coxon, F., Middleton, G.W., Smith, D., Evans, L., Slater, S., Waters, J., Ford, D., Hall, M., Iveson, T.J., Petty, R.D., Plummer, C., Allum, W.H., Blazeby, J.M., Griffin, M., Cunningham, D.

“…Peri-operative chemotherapy and surgery is a standard treatment of localised oesophagogastric adenocarcinoma; however, the outcomes remain poor. ST03 is a…”
Get full text

Observational study investigating Tolerance Of Anticancer Systemic Therapy In the Elderly (TOASTIE): a protocol by Dearden, Helen, Baxter, Mark A, Martin, Sally, Rowe, Michael, Zucker, Kieran, Jones, Christopher Mark, Olsson-Brown, Anna C, Petty, R D, Swinson, Daniel, Brunner, Clair, Smith, Fiona, Lewis, Anna, Taylor, Sarah, Rodgers, Lisa, Cree, Anthea, Smith, Eleanor

“…IntroductionThe number of older adults diagnosed with cancer is increasing. Older adults are more likely to have pre-existing frailty, which is associated with…”
Get full text

Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice by Zermansky, Arnold G, Petty, Duncan R, Raynor, David K, Freemantle, Nick, Vail, Andy, Lowe, Catherine J

“…Abstract Objective: To determine whether a pharmacist can effectively review repeat prescriptions through consultations with elderly patients in general…”
Get full text

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification by Van Cutsem, E., Bang, Y.-J., Mansoor, W., Petty, R.D., Chao, Y., Cunningham, D., Ferry, D.R., Smith, N.R., Frewer, P., Ratnayake, J., Stockman, P.K., Kilgour, E., Landers, D.

“…Approximately 5%–10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine…”
Get full text

The UK National Oesophagogastric Multidisciplinary Team Meeting: An Initiative From the UK & Ireland Oesophagogastric Group by Booth, M.E., Jones, C.M., Helbrow, J., Mansoor, W., Peters, C.J., Petty, R.D., Underwood, T.J., Smyth, E.C., Crosby, T.

Get full text

Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial by Zermansky, A G, Petty, D R, Raynor, D K, Lowe, C J, Freemantle, N, Vail, A

Get full text

A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity by Petty, R. D., Nicolson, M. C., Skaria, S., Sinclair, T. S., Samuel, L. M., Koruth, M.

“…Background: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which…”
Get full text

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial by Scanlon, E., Lavery, A., Albraikat, M., Stevenson, L., Kennedy, C., Byrne, R., Walker, A., Mullan-Young, B., McManus, D.T., Virdee, P.S., Elhussein, L., Turbitt, J., Collinson, D., Miedzybrodzka, Z., Van Schaeybroeck, S., McQuaid, S., James, J.A., Craig, S.G., Blayney, J.K., Petty, R.D., Harkin, D.P., Kennedy, R.D., Eatock, M.M., Middleton, M.R., Thomas, A., Turkington, R.C.

“…The Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC) trial reported an acceptable safety profile for neoadjuvant oxaliplatin and capecitabine (Xelox)…”
Get full text

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma by Baxter, M.A., Spender, L.C., Cairns, D., Walsh, S., Oparka, R., Porter, R.J., Bray, S., Skinner, G., King, S., Turbitt, J., Collinson, D., Miedzybrodzka, Z.H., Jellema, G., Logan, G., Kennedy, R.D., Turkington, R.C., McLean, M.H., Swinson, D., Grabsch, H.I., Lord, S., Seymour, M.J., Hall, P.S., Petty, R.D.

“…An improved understanding of which gastroesophageal adenocarcinoma (GOA) patients respond to both chemotherapy and immune checkpoint inhibitors (ICI) is…”
Get full text

Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study by MCNALLY, O. M, DELANEY, E, PETTY, R. D, CRUICKSHANK, M. E, HUTCHEON, A. W, PARKIN, D. E

“…NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with…”
Get full text

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas by Bain, G H, Collie-Duguid, E, Murray, G I, Gilbert, F J, Denison, A, Mckiddie, F, Ahearn, T, Fleming, I, Leeds, J, Phull, P, Park, K, Nanthakumaran, S, Matula, K M, Grabsch, H I, Tan, P, Welch, A, Schweiger, L, Dahle-Smith, A, Urquhart, G, Finegan, M, Petty, R D

Get full text

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas by Bain, G H, Collie-Duguid, E, Murray, G I, Gilbert, F J, Denison, A, Mckiddie, F, Ahearn, T, Fleming, I, Leeds, J, Phull, P, Park, K, Nanthakumaran, S, Matula, K M, Grabsch, H I, Tan, P, Welch, A, Schweiger, L, Dahle-Smith, A, Urquhart, G, Finegan, M, Petty, R D

Get full text

Explanations for variations in clopidogrel prescribing in England by Petty, D. R., Silcock, J.

“…Background The National Audit Office (NAO) has produced prescribing indicators that Primary Care Trusts (PCTs) can use to judge their performance. One of the…”
Get full text

RCPE UK Consensus Conference on 'approaching the comprehensive management of atrial fibrillation: evolution or revolution?' by Stott, D J, Dewar, R I, Garratt, C J, Griffith, K E, Harding, N J, James, M A, Lane, D A, Petty, D R, Smith, P A, Somerville, M H, Trueland, J

Get full text

A Case of Multiple Linseeds Mimicking Polyposis Coli on Double Contrast Barium Enema by Petty, D.R., Mannion, R.A.J.

Get full text

The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs : Its role in the improvement of selective toxicity and the development of new drugs in clinical oncology by PETTY, R. D

Get full text

Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity by Petty, R D, Cree, I A, Sutherland, L A, Hunter, E M, Lane, D P, Preece, P E, Andreotti, P E

“…Many cytotoxic agents act by causing DNA damage, and the p53 tumour suppressor gene is known to be involved in the cellular response to DNA damage. Since…”
Get more information

An update of the systematic review of Barolith intestinal obstruction by Kurer, M. A., Miller, G. V., Petty, D. R., Chintapatla, S.

Get full text

Tumor chemosensitivity and chemoresistance assays by Cree, Ian A., Petty, Russell D., Kurbacher, Christian M., Untch, Michael

Get full text